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Prematurity	
  is	
  not	
  a	
  new	
  phenomena.	
  	
  Advances	
  in	
  medical	
  technology	
  has	
  
allowed	
  for	
  increased	
  survival	
  of	
  the	
  smallest	
  infants	
  with	
  the	
  earliest	
  age	
  being	
  22	
  
to	
  23	
  weeks	
  gestation.	
  	
  Despite	
  the	
  medical	
  advances,	
  these	
  tiny	
  infants	
  are	
  at	
  risk	
  
for	
  numerous	
  postnatal	
  complications.	
  	
  Complications	
  of	
  prematurity	
  can	
  affect	
  
many	
  body	
  systems	
  and	
  include	
  infection,	
  intraventricular	
  hemorrhage,	
  chronic	
  
lung	
  disease,	
  osteopenia,	
  retinopathy	
  of	
  prematurity	
  and	
  necrotizing	
  enterocolitis	
  
(Angert,	
  2009).	
  	
  Prevention	
  is	
  crucial	
  in	
  all	
  these	
  disease	
  states,	
  in	
  particular	
  the	
  use	
  
of	
  probiotics	
  in	
  preventing	
  necrotizing	
  enterocolitis.	
  	
  Bifidobacteria	
  and	
  lactobacilli	
  
are	
  the	
  common	
  intestinal	
  flora	
  found	
  in	
  term,	
  breastfed	
  infants.	
  	
  Preterm	
  infants	
  
lack	
  this	
  normal	
  flora.	
  	
  	
  Probiotics	
  such	
  as	
  Bifidobacteria	
  and	
  Lactobacillus	
  are	
  live	
  
microbial	
  supplements	
  that	
  	
  are	
  intended	
  to	
  colonize	
  and	
  normalize	
  the	
  intestines	
  of	
  
premature	
  infants	
  in	
  an	
  effort	
  to	
  prevent	
  the	
  overgrowth	
  of	
  pathogenic	
  organisms	
  
which	
  can	
  lead	
  to	
  necrotizing	
  enterocolitis.	
  	
  	
  	
  “The	
  evidence	
  that	
  probiotics	
  reduce	
  
mortality	
  rates	
  is	
  as	
  conclusive	
  as	
  that	
  for	
  surfactant	
  for	
  respiratory	
  distress	
  
syndrome,	
  cooling	
  for	
  hypoxic	
  ischemic	
  encephalopathy,	
  or	
  antenatal	
  
corticosteroids	
  for	
  threatened	
  preterm	
  labor”	
  (Tarnow-Mordi, Wilkinson, Trivedi, &
Brok, 2010, p. 1069). 	
  
	
  
Definition	
  and	
  Description	
  of	
  the	
  Disease	
  
Necrotizing enterocolitis (NEC) is a common gastrointestinal emergency that
affects as many as 14% of very low birth weight (VLBW) preterm infants in the neonatal
intensive care unit (NICU) (Lin et al., 2008). The mortality rate for infants diagnosed
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with NEC is 20-50% with higher mortality rates corresponding to greater bowel
involvement (Gibbins, Maddalena, & Golec, 2008). The exact cause of NEC remains
unknown but many factors are believed to contribute to NEC. These include prematurity,
enteral feeding, intestinal ischemia and bacterial colonization (Lin et al., 2008). The
incidence of NEC is inversely related to birth weight and gestation. Medical
management of NEC is aimed at preventing progression. If NEC is suspected, enteral
feeds are stopped, IV fluids are started, nasogastric decompression is initiated, and IV
antibiotics started. Lab values and serial abdominal x-rays are conducted. In some cases
NEC progresses despite medical management and surgery is needed for peritoneal
drainage or bowel resection (Ladd and Ngo, 2009).
Four risk factors are believed to contribute to NEC. The first risk factor is
prematurity. NEC occurs in 5-10% of all infants less than 1500 grams at birth. The
second risk factor is enteral feedings. Although NEC occurs weeks after feedings are
started, it usually occurs when full feeding amounts are achieved. Infection is the next
risk factor although no specific bacterium has been pinpointed. Normal intestinal flora
consisting of lactobacilli and bifidobacerium are not evident in preterm infants until three
to four weeks after birth. This lack of normal flora is attributed to late start of enteral
feedings and use of broad-spectrum antibiotics. Mucosal injury or ischemia is the fourth
risk factor but it is unclear if ischemia is the cause of NEC as in asphyxia or the result of
NEC from the mucosal inflammation (Gibbs, Lin and Holzman (2007).
Hammerman and Kaplan (2006) explain the microflora of infant intestines and
how probiotics can help with restoring normal flora and thereby reduce the incidence of
NEC. A newborn gut is sterile until birth. A normal, full term, breastfed newborn will
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colonize a variety of intestinal bacteria with bifidobacteria being the dominant one. The
preterm infant has a much different colonization due to the delayed start of feedings and
use of broad-spectrum antibiotics, with a smaller number of bacterial strains. Those that
are present are usually pathogenic and include klebsiella, enterobacter and clostridium
organisms. The appearance of the normal bifidobacteria usually does not occur in the
preterm infants until 2-3 weeks after birth, making the preterm infant more susceptible to
NEC. Underwood, et al. concluded probiotics did increase bifidobacteria in the preterm
infants (2009). In addition, many probiotic clinical trials have been conducted outside
the United States, which have shown a significant decrease in the incidence of NEC in
preterm infants greater than 1000 grams (Ladd and Ngo, 2009).
The sequelae of infants who survive NEC include short-gut syndrome, poor
growth, prolonged initial hospitalization, multiple re-hospitalizations and poor long-term
neurodevelopment (Martin & Walker, 2008). Preventing NEC is instrumental in
decreasing the morbidity and mortality from this gastrointestinal emergency. Evidence
based studies have shown a decrease in NEC in breast fed babies and conservative
trophic feedings. Other experimental methods of prevention include antenatal steroids,
enteral antibiotics, and probiotics (Ladd and Ngo, 2009). The use of probiotics is an
inexpensive, safe and effective treatment for the prevention of NEC.
	
  
Current	
  Review	
  of	
  Evidence-Based	
  Literature	
  
The literature was searched for information about the use of probiotics in the
prevention of necrotizing enterocolitis. An electronic search of CINAHL and MEDLINE
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databases was performed using keywords necrotizing enterocolitis and probiotics. The
time frame searched was from 2000 to 2010.
Hammerman and Kaplan (2006) compare four clinical trials that used probiotics
in preterm infants and evaluated the incidence of NEC. Three out of the four studies
demonstrated a decreased incidence of NEC with relative risk: 0.395 (95% CI, 0.2790.559) and P < 0.001. One of the four studies showed a decrease in mortality from
probiotic use. The overall result was not significant with a relative risk of 0.896 (95%
CI, 0.709-1.132) and P = 0.388. None of the four studies showed a significant increase or
decrease in sepsis with overall relative risk: 1.02 (95% CI, 0.801-1.302) and P = 0.913.
Finally the authors concluded probiotics are a safe, noninvasive, disease-preventing
option that should be considered a treatment option in neonatology. “Their efficacy in
preventing NEC renders them a most attractive addition to the clinical armamentarium.
To date, very few other strategies have been proven definitively to be efficacious in
decreasing the incidence of NEC (Hammerman and Kaplan, 2006, p. 282).
In the summary of their multicenter randomized controlled trial, Lin et al. begin
with presenting the problem of NEC and the possible contributing factors. The authors
explain that previous clinical trials found probiotics decreased the incidence of NEC but
these trials failed to define optimal strains, timing, dosage and duration. The hypothesis
was clearly stated. The method was a prospective, randomized, masked, controlled trial
involving seven NICU’s in Taiwan. The population included 443 preterm infants with
birth weight less than 1500 grams and they were randomized to a group that received
Infloran, a probiotic, with breast milk twice per day or a group that received breast milk
alone. Inclusion and exclusion criteria were defined. Parental consent was obtained and
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approval was given by the IRB before initiation of the study. Death or NEC occurred in
4 out of 217 infants in the study group and 20 out of 217 in the control group. The NNT
to prevent one case of NEC was 20 infants and the NNT to prevent 1 death or case of
NEC was 14. A post-hoc analysis was done to evaluate for bias or center variations.
Final conclusions support the use of the probiotics containing B bifidum and L
acidophilus for six weeks to decrease the incidence of NEC in VLBW preterm infants.
Underwood, et al. explain how the preterm infant lacks the important normal
bacteria that are needed for growth and good health. Discussion of the variety of
outcomes from previous probiotic studies reveals that the differences occurred based on
the infants gestational age and the type of probiotic used. The team of researchers
investigated three groups, two of the groups received two different commercially
produced probiotics and the third group received a placebo. This was a double blind,
placebo-controlled, randomized study that evaluated the effect of probiotics on weight
gain, fecal microbiota and fecal short-chain fatty acid content of the preterm population.
The study was IRB approved and parental consent was obtained. Inclusion and exclusion
criteria were identified. The data collection and analysis was scientifically thorough.
The first result of the study revealed the actual make up of the probiotics differed from
their advertised labels. The study revealed no significant difference in weight gain
between the placebo and intervention groups. Final stool samples revealed a significant
difference in the bacteria between the intervention and placebo groups. The intervention
groups showed a large colonization of bifidobacteria, similar to a term breast-fed infant,
whereas the placebo group showed low counts of bifidobacteria, typical of a preterm
infant. This was the first study in the United States to compare two probiotic products to
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a placebo. The study revealed different make up in the advertised versus actual
compositions of the probiotics. Although the study revealed advantageous differences in
the fecal bacteria composition between the intervention and control groups, it also
revealed the issue of purity of probiotics and questioned their use in the vulnerable
preterm population. Finally the authors recommended more large, multi-centered trials
before the widespread use of probiotics is implemented in the preterm population.

Final analysis revealed two meta-analysis articles. The first is Probiotics for
Prevention of Necrotizing Enterocolitis in Preterm Infants (2008). In this Cochran
review AlFaleh and Bassler compare probiotic versus placebo or no treatment in the
prevention of NEC and/or sepsis in preterm infants. Standard Cochrane search strategy
was used and only quasi-randomized or randomized trials were included. Inclusion
criteria was preterm infants less than 37 weeks and/or less than 2500 grams. Nine trials,
consisting of 1425 infants were included. Specific data related to VLBW infants could
not be extrapolated. The meta-analysis revealed probiotics decreased the incidence of
stage II or greater NEC with a relative risk of 0.32 (95% CI, 0.17-0.60. Probiotics also
reduced mortality from NEC with the relative risk 0.43 (95% CI, 0.25-0.75). No
significant change in sepsis incidence was noted, relative risk 0.93 (95% CI, 0.70-1.19).
Final analysis did reveal that probiotics did significantly reduce the incidence of severe
NEC and a practice change was recommended for preterm infants greater than 1000
grams.
The second article is Updated Meta-analysis of Probiotics for Preventing
Necrotizing Enterocolitis in Preterm Neonates (2010) by Deshpand, Rao, Patole, &

PROBIOTICS	
  AND	
  NEC	
  
	
  

8	
  

Bulsara. Cochrane Central register, Medline, Embase and Cinahl databases were
searched with a total of eleven (N = 2176) trials included in the meta-analysis. A greater
number of infants in the control group (no probiotics) developed NEC compared with the
group that received the probiotics, with a relative risk: 0.35 (95% CI, 0.23-0.55) and P <
0.00001. The number need to treat (NNT) to prevent one case of NEC was 25. Probiotic
use did not show a significant decrease in sepsis, with relative risk 0.98 (95% CI, 0.811.18) and P = 0.80. Probiotic use also showed a significant decrease in mortality, with
relative risk 0.42 (95% CI, 0.29-0.62 and P < 0.00001. NNT to prevent 1 death was 20.
A sensitivity analysis of five trials (N = 1717) revealed decreased NEC in the probiotic
group with relative risk of 0.29 (95% CI, 0.17 – 0.59) and P < 0.00001 and a decreased
mortality with relative risk 0.39 (95% CI, 0.25-0.59) and P < 0.00001. All the included
trials had a Jadad quality score of =/> 3. “Overall, the results of our updated systemic
review and meta-analysis (11 good quality RCT’s and N = 2176) confirm the dramatic
benefits of probiotic supplements in reducing the risk for death and for definite NEC in
preterm VLBW neonates”, with VLBW infants defined as less than 1500 grams.
(Deshpand, et al, 2010, p. 925).

Diagnosing NEC
Necrotizing enterocolitis is an inflammatory bowel disease that mainly affects
preterm infants. The exact pathophysiology of NEC remains unknown but it is thought to
be a multi-factorial process. Intestinal ischemia with reperfusion, bacteria in the gut and
enteral feedings can activate inflammatory mediators, which are thought to contribute to
the pathophysiology of NEC. Once the inflammatory mediators are activated, the
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premature infant is unable to modulate this response. This is the common pathway for
the disease, which can lead to bowel injury and or death. Although the exact cause of
NEC remains unknown, the key to decreasing the incidence of this catastrophic disease is
prevention. Trials on different feeding strategies have been investigated, comparing
earlier feeding introduction to delayed feeding. Neither feeding plan proved to decrease
the incidence of NEC. Other randomized controlled trials have investigated the use of
IGA and IGG in the prevention of NEC with no significant reduction noted.
Prophylactic antibiotics have also been considered but the risks outweigh the benefits.
Only three preventative treatment strategies have been shown to give some protection
against NEC and are the only promising preventative measures in the prevention of NEC
(Gibbins, Maddalena and Golec, 2008):
• The exclusive use of maternal breast milk
• Standardized feeding protocols, specifically advancing feedings cautiously
by a priori decisions not just early versus delayed feeding
• Prophylactic probiotics
The clinical presentation of NEC can be very non-specific and insidious or it can
present as a catastrophic emergency leading to shock and possibly death in a short time
period. The signs and symptoms include apnea, bradycardia, oxygen desaturation,
lethargy, irritability, temperature instability, abdominal distention, abdominal tenderness,
absent bowel sounds, feeding intolerance, abdominal wall cellulitis, blood in the stool,
emesis, and increased gastric residuals. Diagnostic laboratory abnormalities include
metabolic acidosis, thrombocytopenia, leucopenia, leukocytosis with increased band
cells, glucose instability, hyponatremia, coagulation abnormalities, and increased C-
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reactive protein. Finally radiographic abnormalities include intestinal dilatation, presence
of fixed loop of the dilated bowel, thickening of the intestinal wall, ascites, air in the
portal venous system pneumatosis intestinalis, which is the accumulation of hydrogen gas
in the bowel wall by fermentation of carbohydrates by gas-producing organisms and
pneumopeironeum (Thompson and Bizzarro, 2008).
A staging system for classifying NEC was introduced by Bell and colleagues in
1978. This staging system breaks NEC down into 3 stages. Stage I is suspected NEC and
includes the symptoms of temperature instability, apnea and bradycardia, lethargy,
increased gastric residuals, mild abdominal distention, emesis, and bloody stools.
Radiographic findings would show normal or mild intestinal dilatation or mild ileus.
Stage II is Definitive NEC and includes all the symptoms of stage one and in addition
there is an absence of bowel sounds, abdominal tenderness, mild metabolic acidosis and
mild thrombocytopenia. Radiographic studies show intestinal dilatation, ileus or
pneumatosis intestinalis. Finally stage 3 NEC is the most severe and includes all the
symptoms of stage I and II and in addition there is severe apnea and bradycardia,
respiratory and metabolic acidosis, neutropenia, thrombocytopenia and disseminated
intravascular coagulation (Gibbins, et al, 2008). Bell’s NEC classification system is
further divided in to class A and B in each stage as listed below in Table 1 (Hughes, Baez
& McGrath, 2009).
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TABLE 1
Stage	
  I:	
  suspected	
  NEC	
  
A.	
  Systemic	
  signs	
  are	
  nonspecific,	
  including	
  apnea,	
  bradycardia,	
  lethargy,	
  and	
  temperature	
  
instability.	
  
B.	
  Intestinal	
  finding	
  include	
  feeding	
  intolerance,	
  recurrent	
  gastric	
  residuals,	
  and	
  guaiac-‐positive	
  
stools.	
  
C.	
  Radiographic	
  findings	
  are	
  normal	
  or	
  nonspecific.	
  
In	
  stage	
  IB,	
  the	
  diagnosis	
  is	
  the	
  same	
  as	
  stage	
  IA,	
  with	
  the	
  addition	
  of	
  grossly	
  bloody	
  stool.	
  
	
  
Stage	
  II	
  is	
  the	
  definite	
  diagnosis	
  of	
  NEC.	
  	
  
Stage	
  IIA:	
  mild	
  NEC	
  
A.	
  Systemic	
  signs	
  are	
  similar	
  to	
  those	
  in	
  stage	
  I.	
  	
  
B.	
  Intestinal	
  findings	
  include	
  prominent	
  abdominal	
  distention	
  with	
  or	
  without	
  tenderness,	
  
absent	
  bowel	
  sounds,	
  and	
  gross	
  blood	
  in	
  stools.	
  	
  
C.	
  Radiographic	
  findings	
  include	
  ileus,	
  with	
  dilated	
  loops	
  with	
  focal	
  areas	
  of	
  pneumatosis	
  
intestinalis.	
  	
  
	
  
Stage	
  IIB:	
  moderate	
  NEC	
  
A.	
  System	
  signs	
  include	
  stage	
  I	
  signs	
  plus	
  mild	
  acidosis	
  and	
  thrombocytopenia.	
  
B.	
  Intestinal	
  findings	
  include	
  increasing	
  distention,	
  abdominal	
  wall	
  edema,	
  and	
  tenderness	
  with	
  
or	
  without	
  a	
  palpable	
  mass.	
  
C.	
  Radiographic	
  findings	
  include	
  extensive	
  pneumatosis	
  and	
  early	
  ascites	
  intrahepatic	
  portal	
  
venous	
  gas	
  may	
  be	
  present.	
  
	
  
Stage	
  III:	
  advanced	
  NEC	
  
Stage	
  IIIA:	
  advanced	
  NEC	
  
A.	
  Systemic	
  findings	
  include	
  respiratory	
  and	
  metabolic	
  acidosis,	
  assisted	
  ventilation	
  for	
  apnea,	
  
decreasing	
  blood	
  pressure	
  and	
  urine	
  output,	
  neutropenia,	
  and	
  coagulopathy.	
  
B.	
  Intestinal	
  findings	
  include	
  spreading	
  edema,	
  erythema,	
  or	
  discoloration,	
  and	
  induration	
  of	
  the	
  
abdominal	
  wall.	
  	
  
C.	
  Radiographic	
  findings	
  include	
  prominent	
  ascites,	
  paucity	
  of	
  bowel	
  gas,	
  and	
  possibly	
  a	
  
persistent	
  sentinel	
  loop.	
  
	
  
Stage	
  IIIB:	
  advanced	
  NEC	
  
A.	
  Systemic	
  findings	
  reveal	
  generalized	
  edema	
  deteriorating	
  vital	
  signs	
  and	
  laboratory	
  indices,	
  
refractory	
  hypotension,	
  shock	
  syndrome,	
  disseminated	
  intravascular	
  coagulation,	
  and	
  
electrolyte	
  imbalance.	
  	
  
B.	
  Intestinal	
  findings	
  reveal	
  a	
  tense,	
  discolored	
  abdomen	
  and	
  ascites.	
  	
  
C.	
  Radiographic	
  findings	
  commonly	
  show	
  absent	
  bowel	
  gas	
  and	
  often	
  evidence	
  of	
  
intraperitoneal	
  free	
  air.	
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Treatment and Prevention of NEC
Treatment of NEC is divided into two categories: medical and surgical
interventions, which is based on the degree of disease as categorized by the Bell staging
system. Medical treatment entails resting the bowel by stopping all enteral feedings,
placing a nasogastric tube to low intermittent suction, and initiation of intravenous fluids
usually total parenteral nutrition with intravenous lipids. A full septic workup including
blood culture, urine culture and cerebral spinal fluid culture should be performed to
identify the bacteria that may have caused NEC. After cultures are obtained, intravenous
antibiotics must be initiated and would include ampicillin and vancomycin for grampositive organism coverage, gentamicin and cefotaxime for gram-negative organisms,
and metronidazole and clindamycin for anaerobic organisms (Thompson and Bizzarro,
2008). Bowel rest and antibiotics should continue for 7-14 days and antibiotics adjusted
based on cultures and sensitivities. Finally, serial radiographic studies must be performed
to monitor disease status. Surgical intervention is usually indicated if progression of
disease has advanced to Bell’s stage III. Exploratory laporatomy is done to identify and
remove and necrotic bowel.
Prevention is instrumental to decreasing the incidence of NEC. There are five
interventions that have proven to be instrumental in decreasing NEC. These are antenatal
corticosteroids, trophic feedings, breast milk, oral antibiotics and most recently probiotics
(Thompson and Bizzarro, 2008). Gibbins, Maddalena and Golec found that only three
measures were proven to decrease the incidence of NEC and these are breast milk,
standardized feeding protocols and probiotics (2008). Probiotics and breast milk are the
two prevention measures found in both investigations.
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“Probiotics are defined as live microbial supplements that colonize the intestine
and provide benefit to the host. Benefits of probiotics are normalization of intestinal
mucosal barrier function, protection of the gut from pathogens, decreased inflammatory
processes, increased anti-inflammatory cytokines, improved enteral nutrition, and
reduced infection rates secondary to bacterial translocation” (Gibbins et al, p. 147, 2009).
Probiotics are thought to prevent NEC by encouraging competitive colonization,
producing organic acids that decrease pH and inhibit growth of pathogens, increasing
peristalsis, modulating immune response, producing anti-inflammatory cytokines,
competing for pathogen binding and receptor sites, producing bactericocins, influencing
intestinal mucosa to enhance mucin production, stimulating IgA production and
enhancing enteral nutrition (Hughes, et al, 2009). The research that has been conducted
demonstrates that the use of probiotics does reduce the incidence of NEC.
Patient and Family Counseling
An infant diagnosed with NEC can be a very scary situation for the parents of the
infant. Parents should immediately be informed of their infant’s change in status and the
results of preliminary tests and findings. Parents need to be involved in the decisionmaking process and be allowed to consider all the options along the care continuum.
When prognosis is grim and treatment is futile, parents need to be given some time to
come to terms with the challenging diagnosis. “Referred to as ‘the temporal gap,’ parents
are often several days behind caregivers in grasping condition and prognosis and have
little or no experience on which to draw upon” (Gibbins, et al, p.150, 2009). In turn,
parents will be left to make some difficult decisions, which need to be supported, and
family-centered care must be central to the care of the infant.
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Patient and Family Education

Both family education and family counseling must be included in the plan of care.
Education is giving the family the information in a clear and concise manner. Counseling
is giving families the emotional support to deal with the new diagnosis. NEC can be a
potentially fatal diagnosis for a preterm infant. Early parent education about the
complications of prematurity should include prevention of NEC with the use of probiotic
supplementation in preterm infants. Education and prevention are key components to
eliminating the problem of necrotizing enterocolitis in the preterm infant population.
Caring for an infant with NEC involves a multi-system approach. Family
education is one are that can sometimes be forgotten but is very important in the care of
the infant with NEC. First, parents need to be informed immediately in the infant’s
change in status. Informing parents of the preliminary diagnosis including possible
outcomes and options. The use of Bell’s NEC classification system is a helpful tool in
visually detailing the stages of NEC. The family needs to be included in the consultation
process with specialists. The family will need time to come to terms with the new,
potentially life-threatening diagnosis. Finally the family needs to be given all the options
along the continuum of care.

Conclusion
Necrotizing enterocolitis is a devastating condition that still has no exact etiology
and no specific therapy. Prematurity is a predisposing risk factor for NEC. Preterm
infants are known to have altered intestinal flora. Probiotics are promising therapy in
establishing normal intestinal flora in the preterm infant. The clinical trials to date have
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shown some benefit in the use of probiotics for the prevention of NEC in preterm infants.
The problem is that each clinical trial has treated different populations, used different
outcome measures and used different probiotic organisms. FDA approval of probiotic
preparations that have proven to decrease the incidence of NEC could significantly help
to reduce this devastating disease. Probiotics have the potential to become a clinical
breakthrough in the prevention of necrotizing enterocolitis in the preterm infant.

Internet Resources for Families
http://www.prematurity.org
http://www.marchofdimes.org
http://www.neonatology.org
http://www.aap.org/sections/perinatal/families.html
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